Journal article
Expression and immunogenicity of the cancer-testis antigen CT7 (MAGE-C1) in patients with multiple myeloma
- Curioni Fontecedro, A. University Hospital, Zurich, Switzerland
- Knights, A. J. University Hospital, Zurich, Switzerland
- Tinguely, M. University Hospital, Zurich, Switzerland
- de la Rosa, O. University Hospital, Zurich, Switzerland
- Lopes, B. University Hospital, Zurich, Switzerland
- Moch, H. University Hospital, Zurich, Switzerland
- Renner, C. University Hospital, Zurich, Switzerland
- Zippelius, A. University Hospital, Zurich, Switzerland
- Knuth, A. University Hospital, Zurich, Switzerland
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2007, vol. 25, no. 18_suppl, p. 8112-8112
English
8112 Introduction: CT7 (MAGE-C1) is an antigen with restricted expression in cancer and testis (CT antigen). It has been demonstrated to be expressed in more than 55% of Multiple Myeloma (MM) bone marrow biopsies (BMB). CT7 immunogenicity was so far unknown. Thus we aimed to analyse the immune response of MM patients towards CT7. Moreover, we evaluated correlations between CT7 expression and prognostic features. Methods: The CT7 gene was cloned from a MM cell line by RT-PCR; the protein has been expressed in E. coli, purified by affinity FPLC and analysed by Mass Spectrometry. MM patients’ sera (1:200 dilution) were analysed towards the CT7 full length protein by Western Blot (WB) and against truncated CT7 by WB and ELISA. BMB were analyzed by immunohistochemistry (IC) for CT7 expression and for proliferation/differentiation markers. Specific chromosomal aberrations were investigated by FISH analysis. Results: Both full-length and truncated proteins have been produced and fully sequenced. Out of 55 patients’ sera 12 typed positive for the full length protein by WB analysis. Ten of sixteen (62.5%) BMB were positive for CT7. So far no correlation with prognostic features was established. Conclusions: For the first time the in vivo immunogenicity of CT7 was demonstrated. Our preliminary data indicate that spontaneous anti-CT7 humoral responses occur in a significant proportion of MM patients. All detectable humoral responses observed to date are in patients with advanced disease. Characterization of antibody-binding sites and specific CD8/CD4 T cell responses in MM patients is on-going. Our data support the broad and strong expression of CT7 in patients with MM. To date CT7 represent the most immunogenic cancer testis antigen in MM. No significant financial relationships to disclose.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1200/jco.2007.25.18_suppl.8112
- ISSN 0732-183X
- Persistent URL
- https://sonar.ch/global/documents/144590
Statistics
Document views: 11
File downloads: